A Discussion On: Third Party Insurance for Psychedelic Assisted Therapy
PharmAla Biotech Investors Webinar
MDMA: Real World Efficacy Explored
FDA: Guidance | A Discussion On Psychedelic Regulations Globally
Optimizing Clinical Trial Design and The State of the Market
'Cortexa' explained. A Discussion on PharmAla Biotech and Vitura Health Limited Recent JV
Psychedelics Today: Manufacturing MDMA and Why Creating MDMA Analogs Is So Important
The Dales Report - Pharmala Stock Succeeds Through Tough Markets
Changes Announced By The TGA & What It Means For Psychedelics Webinar
PharmAla Biotech | Planning Psychedelic Trials & Navigating the Import/Export Process Webinar
PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia
PharmAla Biotech signs supply deal with Global Wellness Strategies to provide MDMA for trial
Psychedelics 101 | February 8, 2022
Rick Doblin, Exec. Director, MAPS & Nick Kadysh, President & CEO, PharmAla Biotech | MDMA Conference